KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Merck announced Phase 3 KEYNOTE-C93 results showing KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% versus platinum doublet chemotherapy (HR=0.57; p=0.0002) in dMMR advanced or recurrent endometrial cancer. Median progression-free survival was 38.2 months with KEYTRUDA versus 8.4 months with chemotherapy — more than four times longer — after a median follow-up of 36.7 months. Safety was consistent with prior studies, with Grade ≥3 treatment-related adverse events in 18.1% of KEYTRUDA patients versus 50.7% on chemotherapy, and no new safety signals identified.
Key figures
- Drug Name
- KEYTRUDA (pembrolizumab)
- Phase Of Trial
- Phase 3
- P value
- 0.0002
- Orr chemo
- 62.1%
- Orr keytruda
- 64.1%
- Hazard ratio pfs
- 0.57
- Enrolled patients
- 299
- Pfs risk reduction
- 43%
- Grade3plus trae chemo
- 50.7%
- Median pfs chemo months
- 8.4
- Grade3plus trae keytruda
- 18.1%
- Median pfs keytruda months
- 38.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.